Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Ganesan Ramamoorthi"'
Autor:
Ganesan Ramamoorthi
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/ac31cfee485b457ab204f519482aeab0
Autor:
Krithika Kodumudi, Brian J Czerniecki, Doris Wiener, Ganesan Ramamoorthi, Colin Snyder, Payal Grover, Hongtao Zhang, Mark I Greene, Amrita Basu, Corey Gallen, Ricardo L B Costa, Hyo S Han, Gary Koski
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/9e2a2406075545b5b9bb56bb7d2d2658
Autor:
Nadia Nocera Zachariah, Amrita Basu, Namrata Gautam, Ganesan Ramamoorthi, Krithika N. Kodumudi, Nagi B. Kumar, Loretta Loftus, Brian J. Czerniecki
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Breast cancer (BC) prevention remains the ultimate cost-effective method to reduce the global burden of invasive breast cancer (IBC). To date, surgery and chemoprevention remain the main risk-reducing modalities for those with hereditary cancer syndr
Externí odkaz:
https://doaj.org/article/ec880474820f49c39ed7097d18ed36b6
Autor:
Amrita Basu, Ganesan Ramamoorthi, Gabriella Albert, Corey Gallen, Amber Beyer, Colin Snyder, Gary Koski, Mary L. Disis, Brian J. Czerniecki, Krithika Kodumudi
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Current success of immunotherapy in cancer has drawn attention to the subsets of TH cells in the tumor which are critical for activation of anti-tumor response either directly by themselves or by stimulating cytotoxic T cell activity. However, presen
Externí odkaz:
https://doaj.org/article/b0b91eb05a9543e286852852ed9356e3
Autor:
Krithika N. Kodumudi, Ganesan Ramamoorthi, Colin Snyder, Amrita Basu, Yongsheng Jia, Sabrina Awshah, Amber P. Beyer, Doris Wiener, Lian Lam, Hongtao Zhang, Mark I. Greene, Ricardo L. B. Costa, Brian J. Czerniecki
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Patients with metastatic HER2 breast cancer (MBC) often become resistant to HER 2 targeted therapy and have recurrence of disease. The Panacea trial suggested that HER2 MBC patients were more likely to respond to checkpoint therapy if TIL were presen
Externí odkaz:
https://doaj.org/article/0030af4bce4f4c24a0cb50d21063b785
Publikováno v:
In Life Sciences 15 August 2018 207:284-295
Autor:
Agarwal, Ayushi, Kasinathan, Akiladdevi, Ganesan, Ramamoorthi, Balasubramanian, Akhila, Bhaskaran, Jahnavi, Suresh, Samyuktha, Srinivasan, Revanth, Aravind, K.B., Sivalingam, Nageswaran
Publikováno v:
In Nutrition Research March 2018 51:67-81
Autor:
Dasiram, Jade Dhananjay, Ganesan, Ramamoorthi, Kannan, Janani, Kotteeswaran, Venkatesan, Sivalingam, Nageswaran
Publikováno v:
In Biomedicine & Pharmacotherapy February 2017 86:373-380
Autor:
Gary K. Koski, Amrita Basu, Payal Grover, Qianxing Mo, Hatem Soliman, Brian J. Czerniecki, Hyo S. Han, Mark I. Greene, Doris Wiener, Colin Snyder, Hongtao Zhang, Yong-Zi Chen, Jose R. Conejo-Garcia, Ricardo Costa, Ganesan Ramamoorthi, Zhongsheng Tong, Krithika Kodumudi, Catherine A. Lee, Shari Pilon-Thomas, Yongsheng Jia
Publikováno v:
Molecular Therapy. 29:1541-1556
HER2 breast cancer (BC) remains a significant problem in patients with locally advanced or metastatic BC. We investigated the relationship between T helper 1 (Th1) immune response and the proteasomal degradation pathway (PDP), in HER2-sensitive and -
Publikováno v:
Cancer Research. 83:4056-4056
Human epidermal growth factor receptor 2 (HER2) overexpression accounts for 30% of invasive breast cancer (BC) and is critically associated with aggressive disease, recurrence and metastasis. Adoptive cell therapy approaches using cytotoxic CD8 T cel